<DOC>
	<DOCNO>NCT02781935</DOCNO>
	<brief_summary>The DREAM study assess diagnostic accuracy diffusion-weighted MRI combination image modality ( multiparametric MRI CT Scan ) determine true status disappear liver metastasis ( DLM ) detect conversion systemic therapy unresectable borderline resectable colorectal liver metastasis ( CRLM ) .</brief_summary>
	<brief_title>Diffusion-Weighted MRI Liver Metastasis</brief_title>
	<detailed_description>The advancement systemic local therapy complex CRLM lead increase incidence DLMs . It hypothesize DW-MRI imaging could distinguish metastasis completely sterilize conversion therapy sterilize scar ( non-viable tumor ) . If demonstrate , use DW-MRI could make significant impact surgical decision make process provide surgeon reliable guide decide whether leave behind resect/ablate site DLM . Most importantly , surgical choice also significant impact patient outcome may impact risk local recurrence need re-operation.The possibility improve surgical management complex CRLM foreseen benefit observe resect small residual metastasis DLMs clarify multi-center international prospective study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Eligibility : 1 . Contrastenhanced thorax , abdomen pelvic CT scan ( least portal venous phase liver ) diagnosis right surgery available 2 . Multiparametric MRI baseline right surgery available ( T1/T2 , DWMRI contrast enhance MRI ) . 3. WHO performance status 0 1 4 . Previous treatment ( chemotherapy , surgery ) primary , liver extrahepatic metastasis allow . 5 . No malignancy 3 year prior study entry exception surgically cure carcinoma situ cervix , situ breast cancer , incidental finding stage T1a T1b prostate cancer gleason score â‰¤ 6 , basal/squamous cell carcinoma skin 6 . Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration study Criteria Enrollment 1 . Conversion therapy either give complete 2 . Patient suitable hepatic resection base assessment MDT compose least expert liver/colorectal surgeon , Gastrointestinal ( GI ) radiologist oncologist prior liver surgery 3 . Hepatic resection schedule take place within 8 week late image 1 . Contraindications contrast agent CT MRI MRI procedure 2 . Pregnancy 3 . Significant comorbidity preclude either conversion therapy surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>unresectable colorectal liver metastasis</keyword>
	<keyword>diffusion weight MRI</keyword>
	<keyword>disappear liver metastasis</keyword>
</DOC>